Abstract
Age is an established major risk factor for glaucoma that can be used along with other data to compute chances of developing glaucoma. This leading cause of blindness is becoming increasingly more prevalent in the aging population. The characteristic progressive degeneration of the optic nerve in glaucoma is primarily caused by increased intraocular pressure yet the cause for the reduced outflow is not well understood. Early diagnosis of glaucoma remains difficult. Classic treatment can delay progression of glaucomatous optic neuropathy by lowering intraocular pressure medically or surgically. Recent insights into the age-related molecular changes of the outflow tract and retinal ganglion cells have encouraged search for new treatment approaches. New findings suggest that age related tissue changes themselves contribute significantly and are not just associated. Interdisciplinary research will be necessary to advance understanding, diagnosis and treatment of this neurodegenerative disease that has been known for more than thousand years but to this date remains a challenge.
Keywords: Glaucoma, optic nerve degeneration, outflow, blindness, Aging, oxidation, Beta-Amyloid, Alzheimers's Disease, Senescence, Trabecular Meshmwork
Current Aging Science
Title: Glaucoma and Aging
Volume: 4 Issue: 2
Author(s): Guilherme Guedes, James C. Tsai and Nils A. Loewen
Affiliation:
Keywords: Glaucoma, optic nerve degeneration, outflow, blindness, Aging, oxidation, Beta-Amyloid, Alzheimers's Disease, Senescence, Trabecular Meshmwork
Abstract: Age is an established major risk factor for glaucoma that can be used along with other data to compute chances of developing glaucoma. This leading cause of blindness is becoming increasingly more prevalent in the aging population. The characteristic progressive degeneration of the optic nerve in glaucoma is primarily caused by increased intraocular pressure yet the cause for the reduced outflow is not well understood. Early diagnosis of glaucoma remains difficult. Classic treatment can delay progression of glaucomatous optic neuropathy by lowering intraocular pressure medically or surgically. Recent insights into the age-related molecular changes of the outflow tract and retinal ganglion cells have encouraged search for new treatment approaches. New findings suggest that age related tissue changes themselves contribute significantly and are not just associated. Interdisciplinary research will be necessary to advance understanding, diagnosis and treatment of this neurodegenerative disease that has been known for more than thousand years but to this date remains a challenge.
Export Options
About this article
Cite this article as:
Guedes Guilherme, C. Tsai James and A. Loewen Nils, Glaucoma and Aging, Current Aging Science 2011; 4 (2) . https://dx.doi.org/10.2174/1874609811104020110
DOI https://dx.doi.org/10.2174/1874609811104020110 |
Print ISSN 1874-6098 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-6128 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Development and Clinical use of Prasugrel and Ticagrelor
Current Pharmaceutical Design L-Arginine Analogs – Inactive Markers or Active Agents in Atherogenesis?
Cardiovascular & Hematological Agents in Medicinal Chemistry A Brief Review of Blue- and Bilberries’ Potential to Curb Cardio-Metabolic Perturbations: Focus on Diabetes
Current Pharmaceutical Design Cardiovascular Magnetic Resonance Imaging clarifies cardiac pathophysiology in early, asymptomatic diffuse systemic sclerosis
Inflammation & Allergy - Drug Targets (Discontinued) Preparation and Evaluation of Chitosan Submicroparticles Containing Pilocarpine for Glaucoma Therapy
Current Drug Delivery Toxics of Tobacco Smoke and Cardiovascular System: From Functional to Cellular Damage
Current Pharmaceutical Design Adrenergic Drugs Blockers or Enhancers for Cognitive Decline ? What to Choose for Alzheimer’s Disease Patients?
CNS & Neurological Disorders - Drug Targets Nailfold Capillaroscopy Within and Beyond the Scope of Connective Tissue Diseases
Current Rheumatology Reviews Use of Medication in Coronary Imaging by CT
Current Medical Imaging Neonatal Brain Hemorrhage (NBH) of Prematurity: Translational Mechanisms of the Vascular-Neural Network
Current Medicinal Chemistry Towards a Better Understanding of Cardiac and Vascular Disease in Patients with Chronic Kidney Disease
Current Cardiology Reviews The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease
Current Cardiology Reviews Adiponectin - A Novel Anti-Atherogenic Factor in the Metabolic Syndrome: Mechanisms of Action and Therapeutic Potential
Vascular Disease Prevention (Discontinued) Glycoxidation and Wound Healing in Diabetes: An Interesting Relationship
Current Diabetes Reviews Endothelial Dysfunction and Atherosclerosis: Focus on Novel Therapeutic Approaches
Recent Patents on Cardiovascular Drug Discovery Cross-Talk Between Adipose Tissue Health, Myocardial Metabolism and Vascular Function: The Adipose-Myocardial and Adipose-Vascular Axes
Current Pharmaceutical Design Astrocytes: From the Physiology to the Disease
Current Alzheimer Research Cyclooxygenase and Neuroinflammation in Parkinsons Disease Neurodegeneration
Current Neuropharmacology Recent Advances on Nitric Oxide in the Upper Airways
Current Medicinal Chemistry Biologics for Extraintestinal Manifestations of IBD
Current Drug Targets